Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot)

PHASE3CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

December 25, 2020

Study Completion Date

December 25, 2020

Conditions
Uncomplicated Severe Acute Malnutrition
Interventions
DRUG

Azithromycin

Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.

DRUG

Amoxicillin

Children enrolled in the trial and randomized to azithromycin will receive a 7-day course of oral amoxcillin given in twice-daily doses of 50-100 mg/kg, per the Burkina Faso guidelines for the management of severe acute malnutrition. The first dose will be administered at the time of enrollment and the remaining dose will be administered by the caregiver at home. Enrolled children will also receive RUTF.

Trial Locations (1)

Unknown

Centre de Recherche en santé de nouna, Nouna

All Listed Sponsors
collaborator

Centre de Recherche en Sante de Nouna, Burkina Faso

OTHER_GOV

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of California, San Francisco

OTHER

NCT03568643 - Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot) | Biotech Hunter | Biotech Hunter